Non-Toxic Gel to Treat Vulvovaginal Candidiasis

描述（由申请人提供）：本项目的目标是开发一种用于治疗外阴阴道念珠菌病（WC）的安全杀生物阴道凝胶。WC是由几种空气传播的念珠菌属酵母菌引起的，这些酵母菌是包括阴道在内的几个部位的人类正常居民。C.白念珠菌过去与WC的发生有关，但耐药的非念珠菌。白色念珠菌属越来越多地被认为是WC的原因。许多人：他是非C。白色念珠菌菌株对正常水平的抗真菌药物具有抗性。因此，复发性WC已成为越来越常见和慢性的问题，由于现有治疗的局限性，患者变得难以治疗。生物医学开发公司（BDC）正在评估lova凝胶作为一种新型，安全，有效的杀微生物剂。LOVA凝胶是一种广谱杀生物剂，具有抗病毒、细菌和酵母的活性，不会产生抗性突变体或过敏性。该项目的目标是开发lova阴道凝胶作为外阴阴道念珠菌病的治疗。BDC将执行以下具体目标：具体目标1：配制用于治疗外阴阴道念珠菌病的lova凝胶制剂具体目标2：证明lova凝胶制剂的安全性具体目标3：证明lova凝胶制剂在杀灭浮游念珠菌方面的有效性。具体目标4：证明lova凝胶可有效根除大鼠的持续性白色念珠菌阴道感染，与公共卫生的相关性：阴道炎是全球初级保健中最常见的妇科诊断，估计每年影响10亿女性。WC占阴道炎的30-45%，大约75%的绝经前妇女至少会有一次WC发作。在绝经前妇女中，70- 75%的人至少会有一次WC发作，一半的大学女性在25岁时会有一次WC发作，由医生诊断。在美国，每年处理WC的费用估计为18亿美元。

DESCRIPTION (provided by applicant): The goal of this project is to develop a safe biocidal vaginal gel for treatment of vulvovaginal candidiasis (WC). WC is caused by one of several airborne species of the yeast Candida that are normal inhabitants of humans at several sites, including the vagina. C. albicans has been associated with causing WC in the past, but drug-resistant non-C. albicans spp. are increasingly being identified as the cause of WC. Many of: he non-C. albicans strains are resistant to normal levels of antifungal drugs. As a result, recurrent WC has become an increasingly common and chronic problem, with patients becoming refractory to treatment due to imitations in available therapy. Biomedical Development Corporation (BDC) is evaluating lova gel as a novel, safe, and effective microbicide. lova gel is a broad-spectrum biocide with activity against viruses, bacteria, and yeast, without nducing resistant mutants or allergenicity. The goal of this project is to develop lova vaginal gel as a treatment for vulvovaginal candidiasis. BDC will execute the following specific aims: Specific Aim 1: Formulate lova Gel Formulations for Use in Treating Vulvovaginal Candidiasis Specific Aim 2: Demonstrate Safety of lova Gel Formulations Specific Aim 3: Demonstrate Effectiveness of lova Gel Formulations in Killing Planktonic Candida spp. Specific Aim 4: Demonstrate that lova Gel is Effective in Eradicating a Persistent Candida albicans Vaginal Infection in Rats , Relevance to Public Health: Vaginitis is the most common gynecologic diagnosis in primary care globally, affecting an estimated 1 billion women each year. WC accounts for 30-45% of vaginitis, and approximately 75% of premenopausal women will have at least one episode of WC. Among premenopausal women, 70- 75% will have at least one episode of WC and half of all college women will, by age 25, have had one episode of WC diagnosed by a physician. Annual costs for treating WC in the U.S. are estimated at $1.8 billion.